JPH07503722A - 血中の酸化窒素濃度を増加させる方法 - Google Patents
血中の酸化窒素濃度を増加させる方法Info
- Publication number
- JPH07503722A JPH07503722A JP5513890A JP51389093A JPH07503722A JP H07503722 A JPH07503722 A JP H07503722A JP 5513890 A JP5513890 A JP 5513890A JP 51389093 A JP51389093 A JP 51389093A JP H07503722 A JPH07503722 A JP H07503722A
- Authority
- JP
- Japan
- Prior art keywords
- blood
- concentration
- ozone
- nitric oxide
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 130
- 239000008280 blood Substances 0.000 title claims abstract description 130
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 109
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 44
- 230000005855 radiation Effects 0.000 claims abstract description 14
- 230000001965 increasing effect Effects 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 5
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000001881 impotence Diseases 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 4
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010037075 Protozoal infections Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000036765 blood level Effects 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 55
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 43
- 239000007789 gas Substances 0.000 description 26
- 101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 description 20
- 101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 description 20
- 101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 description 20
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 12
- 238000004220 aggregation Methods 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 9
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000006385 ozonation reaction Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 229910002651 NO3 Inorganic materials 0.000 description 6
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010064719 Oxyhemoglobins Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 229940123134 Nitric oxide inhibitor Drugs 0.000 description 2
- 238000003302 UV-light treatment Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 150000002826 nitrites Chemical class 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241000191291 Abies alba Species 0.000 description 1
- 108010043137 Actomyosin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 241000975417 Oscinella frit Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0023—Agression treatment or altering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/32—Oxygenators without membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0216—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims (23)
- 1.血液を、酸化窒素濃度増強効果のある量のオゾンガス及び紫外線照射と接触 させることを包含する、血中の酸化窒素濃度の増加方法。
- 2.オゾンガスが、血液中で約0.5μg/mlないし約100μg/mlの濃 度を有する、請求項1の方法。
- 3.オゾンガスが約5μg/mlないし約50μg/mlの濃度を有する、請求 項2の方法。
- 4.紫外線照射が約253.7nmの波長を有する請求項1ないし3のいずれか 1項の方法。
- 5.血液を、オゾンガス及び紫外線照射と接触させる間、約0℃ないし約56℃ の温度に保つ、前記請求項のいずれか1項の方法。
- 6.血液を、オゾンガス及び紫外線照射と接触させる間、約37℃ないし約43 ℃の温度に保つ、請求項5の方法。
- 7.血液を、オゾンガス及び紫外線照射と接触させる間、約42.5℃の温度に 保つ、請求項6の方法。
- 8.処理血液が約0.01mlないし約400mlである、前記請求項のいずれ か1項の方法。
- 9.処理血液が約10mlである、請求項8の方法。
- 10.血液を、約3分間、オゾンガス及び紫外線照射と接触させる、前記請求項 のいずれか1項の方法。
- 11.血液がヒトの血液である、前記請求項のいずれか1項の方法。
- 12.前記請求項のいずれか1項による方法によって調製した、酸化窒素の濃度 の増強された血液。
- 13.請求項12による血液の医療用製剤における使用。
- 14.請求項1ないし11のいずれか1項の方法の医療製剤における使用。
- 15.請求項13叉は14による、高血圧治療用医療製剤における使用。
- 16.請求項13叉は14による、神経学的病状治療用製剤における使用。
- 17.請求項13叉は14による、うつ病治療用製剤における使用。
- 18.請求項13叉は14による、腫瘍治療用製剤における使用。
- 19.請求項13叉は14による、細菌感染症治療用製剤における使用。
- 20.請求項13叉は14による、糸状菌感染症治療用製剤における使用。
- 21.請求項13叉は14による、インポテンス治療用製剤における使用。
- 22.請求項13叉は14による、ウイルス感染症治療用製剤における使用。
- 23.請求項13叉は14による、原虫類感染症治療用製剤における使用
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83279892A | 1992-02-07 | 1992-02-07 | |
US832,798 | 1992-02-07 | ||
US94132692A | 1992-09-04 | 1992-09-04 | |
US941,326 | 1992-09-04 | ||
PCT/GB1993/000259 WO1993015779A1 (en) | 1992-02-07 | 1993-02-08 | Method of increasing the concentration of nitric oxide in blood |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07503722A true JPH07503722A (ja) | 1995-04-20 |
JP3989949B2 JP3989949B2 (ja) | 2007-10-10 |
Family
ID=27125561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51389093A Expired - Fee Related JP3989949B2 (ja) | 1992-02-07 | 1993-02-08 | 血中の酸化窒素濃度を増加させる方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5834030A (ja) |
EP (2) | EP0680346B1 (ja) |
JP (1) | JP3989949B2 (ja) |
AT (2) | ATE350046T1 (ja) |
AU (1) | AU681999B2 (ja) |
CA (1) | CA2129630C (ja) |
DE (2) | DE69334101T2 (ja) |
DK (2) | DK1243278T3 (ja) |
ES (2) | ES2179828T3 (ja) |
HK (1) | HK1053068B (ja) |
NZ (1) | NZ249176A (ja) |
PT (2) | PT680346E (ja) |
WO (1) | WO1993015779A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001079083A (ja) * | 1999-09-14 | 2001-03-27 | Jms Co Ltd | 人工肺装置 |
JP2001516723A (ja) * | 1997-09-12 | 2001-10-02 | ヴァソゲン アイルランド リミテッド | ストレスの治療およびストレスに対する予備調整 |
JP2002534473A (ja) * | 1999-01-12 | 2002-10-15 | パヴェル ハメット, | 細胞死に対する予備条件付け |
JP2003509124A (ja) * | 1999-09-16 | 2003-03-11 | バソジェン アイルランド リミテッド | 哺乳動物血液を調整するための装置およびプロセス |
JP2003520244A (ja) * | 2000-01-18 | 2003-07-02 | バソジェン アイルランド リミテッド | 前処理した自己血液によるうっ血性心不全の処置 |
JP2009167223A (ja) * | 2001-11-13 | 2009-07-30 | Univ Duke | 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用 |
JP2017521088A (ja) * | 2014-05-09 | 2017-08-03 | サンクステム エス・アール・エル | 全血から成体幹細胞を増殖させる方法 |
JP2019065039A (ja) * | 2013-02-28 | 2019-04-25 | ニュー・ヘルス・サイエンシーズ・インコーポレイテッドNew Health Sciences, Inc. | 血液処理のためのガス枯渇化およびガス添加デバイス |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204058B1 (en) | 1992-02-07 | 2001-03-20 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US6696092B2 (en) | 1992-02-07 | 2004-02-24 | Vasogen Ireland Limited | Endothelial lining effects and treatment of vasospastic disorders |
US6669965B2 (en) | 1992-02-07 | 2003-12-30 | Vasogen Ireland Limited | Method of treating atherosclerosis |
US5980954A (en) | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
US5910316A (en) * | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
ATE246929T1 (de) * | 1995-05-05 | 2003-08-15 | Vasogen Ireland Ltd | Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen |
AU760465B2 (en) * | 1995-05-05 | 2003-05-15 | Vasogen Ireland Limited | Endothelial lining effects and treatment of vasospastic disorders |
US6866755B2 (en) * | 2001-08-01 | 2005-03-15 | Battelle Memorial Institute | Photolytic artificial lung |
CA2206180A1 (en) * | 1997-05-27 | 1998-11-27 | Vasogen Inc. | Treatment of chronic post-traumatic pain syndromes |
US6087087A (en) * | 1997-07-03 | 2000-07-11 | Takashi Yonetani | Treatment of hemoglobin with nitric oxide |
JPH11217330A (ja) | 1998-01-30 | 1999-08-10 | Sumitomo Pharmaceut Co Ltd | 神経栄養因子分泌促進剤 |
US6264646B1 (en) | 1998-11-13 | 2001-07-24 | Vasogen Ireland Limited | Method for preventing and reversing atherosclerosis in mammals |
US7045124B1 (en) * | 1999-01-12 | 2006-05-16 | Vasogen Irelend Limited | Pre-conditioning against cell death |
AU3877800A (en) | 1999-03-30 | 2000-10-16 | Trustees Of Boston University | Compositions and methods for producing platelets and/or proplatelets from megakaryocytes |
CA2271190A1 (en) | 1999-05-06 | 2000-11-06 | Vasogen Ireland Limited | Improved method for treating mammals with modified mammalian blood |
US7516742B2 (en) | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
CA2309424A1 (en) | 2000-05-25 | 2001-11-25 | Vasogen Ireland Limited | Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
EA005649B1 (ru) | 2000-08-11 | 2005-04-28 | Дэвид Р. Уитлок | Композиции, содержащие аммиакокисляющие бактерии, увеличивающие продуцирование окиси азота и предшественников окиси азота, и способы их использования |
NL1015999C2 (nl) * | 2000-08-23 | 2002-02-26 | A J Van Liebergen Holding B V | Inrichting voor het verwarmen van bloed of andere fysiologische vloeistoffen. |
CA2327630A1 (en) * | 2000-12-05 | 2002-06-05 | Vasogen Ireland Limited | Transforming growth factor regulation |
US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US7335383B2 (en) * | 2001-01-16 | 2008-02-26 | The Regents Of The University Of Michigan | Generation of nitric oxide in vivo from nitrite, nitrate or nitrosothiols endogenous in blood |
US7128904B2 (en) * | 2001-01-16 | 2006-10-31 | The Regents Of The University Of Michigan | Material containing metal ion ligand complex producing nitric oxide in contact with blood |
ES2312547T3 (es) * | 2001-01-16 | 2009-03-01 | The Regents Of The University Of Michigan | Generacion biocatalitica y biomimetica in situ de oxido nitrico en interfases sustrato/sangre. |
US7122208B2 (en) | 2001-04-06 | 2006-10-17 | Vasogen Ireland Limited | Compositions containing apoptotic entities |
CA2465487C (en) * | 2001-08-01 | 2012-03-20 | Bruce F. Monzyk | Photolytic cell for providing physiological gas exchange |
BR0306868A (pt) * | 2002-01-11 | 2005-04-12 | David R Whitlock | Composições incluindo bactérias oxidando amonìaco e métodos para usar as mesmas |
CA2377442A1 (en) * | 2002-03-20 | 2003-09-20 | Thomas Ichim | Increasing tumor oxygen content by administration of stressed cells |
AU2003218583A1 (en) * | 2002-04-10 | 2003-10-27 | Vasogen Ireland Ltd | Electrocardiographic aspects of chf treatment |
US7531133B2 (en) | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
US20100316727A1 (en) * | 2003-07-31 | 2010-12-16 | Latino Joseph S | Treatment of inflammatory disorders with ozone |
US20100316730A1 (en) * | 2003-07-31 | 2010-12-16 | Latino Joseph S | Treatment of cardiovascular diseases with ozone |
US20050189302A1 (en) * | 2003-07-31 | 2005-09-01 | Latino Joseph S. | Viral inactivation using ozone |
US7736494B2 (en) * | 2003-07-31 | 2010-06-15 | Acquisci, Inc. | Ozone delivery system including a variable pitch gas-fluid contact device |
US20050051497A1 (en) * | 2003-07-31 | 2005-03-10 | Latino Joseph S. | Viral inactivation using ozone |
US20100318014A1 (en) * | 2003-07-31 | 2010-12-16 | Latino Joseph S | Treatment of acute ischemic brain stroke with ozone |
BRPI0414813A (pt) * | 2003-09-26 | 2006-11-14 | David R Whitlock | método para o uso de bactéria que oxidam a amÈnia |
CN100475275C (zh) * | 2004-01-05 | 2009-04-08 | 董永华 | 肿瘤血管栓塞剂及其储存和释放装置 |
US8518457B2 (en) | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
AU2005244078A1 (en) | 2004-05-11 | 2005-11-24 | Pulmonox Technologies Corporation | Intermittent dosing of nitric oxide gas |
EP1773360A4 (en) * | 2004-07-20 | 2009-09-02 | Vasogen Ireland Ltd | TREATMENT OF ACUTE INFLAMMATORY EVENTS |
CN100420490C (zh) * | 2005-04-13 | 2008-09-24 | 刘余厚 | 全自动紫外线照射充氧自血回输处理方法及设备 |
US20080241208A1 (en) * | 2005-06-30 | 2008-10-02 | Charles Shanley | Methods, Compositions and Devices For Promoting Anglogenesis |
WO2007064895A2 (en) * | 2005-12-02 | 2007-06-07 | The Regents Of The University Of Michigan | Polymer compositions, coatings and devices, and methods of making and using the same |
US8079998B2 (en) | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
US20080181832A1 (en) * | 2007-01-30 | 2008-07-31 | Lih-Ren Shiue | Pocket-size ozone generator |
ITMI20131667A1 (it) * | 2013-10-09 | 2015-04-10 | Ind Paolo Gobbi Frattini | Metodo per pre-trattare le cellule ematiche prima della separazione. |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
WO2015160911A2 (en) | 2014-04-15 | 2015-10-22 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
SE541036C2 (en) | 2014-09-15 | 2019-03-12 | Sangair Ab | Apparatus and system for ozonating blood, and method for ozonating blood prior to storage |
EP4295872A1 (en) * | 2022-06-22 | 2023-12-27 | Purotech S.r.l. | Blood treatment apparatus |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US695647A (en) * | 1901-10-30 | 1902-03-18 | James Harold Warner | Combination-tile for floors. |
DE1068428C2 (de) * | 1957-05-21 | 1960-04-21 | Hermann Dr Med Jentjens | Verfahren und Einrichtung zur Herstellung von oxygeniertrm Blut |
US3325641A (en) * | 1964-02-17 | 1967-06-13 | George W Jones | Apparatus for treating a thin film of liquid by exposure to radiant energy |
US3715430A (en) * | 1969-08-04 | 1973-02-06 | E Ryan | Purified oxygen gas containing ozone and higher oxygen polymers |
DE2926523A1 (de) * | 1979-06-30 | 1981-01-22 | Margit Stadtlaender | Geraet zur therapeutischen behandlung von blut und anderen koerpereigenen wie auch koerperfremden fluessigkeiten, substanzen und gasen zum zweck der therapeutischen wie auch diagnostischen anwendung in der human- wie auch veterinaermedinzin usw. |
JPS58198466A (ja) * | 1982-05-12 | 1983-11-18 | Teijin Ltd | 5−チアプロスタグランジン類およびその製造法 |
DD249143A3 (de) * | 1985-03-20 | 1987-09-02 | Ilmenau Tech Hochschule | Vorrichtung zur physiologisch-therapeutisch wirksamen optischen bestrahlung koerpereigenen venenblutes |
US4632980A (en) * | 1985-04-03 | 1986-12-30 | Immunologics | Ozone decontamination of blood and blood products |
DE8704467U1 (ja) * | 1987-01-15 | 1988-05-26 | Quarzlampenfabrik Dr.-Ing. Felix W. Mueller Gmbh & Co Kg, 4300 Essen, De | |
JPH01207070A (ja) * | 1987-10-22 | 1989-08-21 | Jr Robert E Duthie | 滅菌方法および装置 |
ATE120375T1 (de) * | 1988-04-29 | 1995-04-15 | Medizone Int Inc | Vorrichtung für die gesteuerte generierung und verabreichung von ozon. |
US4983637A (en) * | 1988-06-24 | 1991-01-08 | Stephen Herman | Method for treating viral infection of HIV |
US5591457A (en) * | 1992-02-07 | 1997-01-07 | Vasogen Inc | Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human |
-
1993
- 1993-02-08 EP EP93904180A patent/EP0680346B1/en not_active Expired - Lifetime
- 1993-02-08 EP EP02014086A patent/EP1243278B1/en not_active Expired - Lifetime
- 1993-02-08 DK DK02014086T patent/DK1243278T3/da active
- 1993-02-08 DK DK93904180T patent/DK0680346T3/da active
- 1993-02-08 PT PT93904180T patent/PT680346E/pt unknown
- 1993-02-08 DE DE69334101T patent/DE69334101T2/de not_active Expired - Fee Related
- 1993-02-08 PT PT02014086T patent/PT1243278E/pt unknown
- 1993-02-08 JP JP51389093A patent/JP3989949B2/ja not_active Expired - Fee Related
- 1993-02-08 AT AT02014086T patent/ATE350046T1/de not_active IP Right Cessation
- 1993-02-08 ES ES93904180T patent/ES2179828T3/es not_active Expired - Lifetime
- 1993-02-08 AT AT93904180T patent/ATE219953T1/de not_active IP Right Cessation
- 1993-02-08 CA CA002129630A patent/CA2129630C/en not_active Expired - Fee Related
- 1993-02-08 NZ NZ249176A patent/NZ249176A/en not_active IP Right Cessation
- 1993-02-08 WO PCT/GB1993/000259 patent/WO1993015779A1/en active IP Right Grant
- 1993-02-08 DE DE69332087T patent/DE69332087T2/de not_active Expired - Fee Related
- 1993-02-08 AU AU35063/93A patent/AU681999B2/en not_active Ceased
- 1993-02-08 ES ES02014086T patent/ES2280454T3/es not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/477,818 patent/US5834030A/en not_active Expired - Fee Related
-
2003
- 2003-03-11 HK HK03101742.6A patent/HK1053068B/zh not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001516723A (ja) * | 1997-09-12 | 2001-10-02 | ヴァソゲン アイルランド リミテッド | ストレスの治療およびストレスに対する予備調整 |
JP2002534473A (ja) * | 1999-01-12 | 2002-10-15 | パヴェル ハメット, | 細胞死に対する予備条件付け |
JP2001079083A (ja) * | 1999-09-14 | 2001-03-27 | Jms Co Ltd | 人工肺装置 |
JP2003509124A (ja) * | 1999-09-16 | 2003-03-11 | バソジェン アイルランド リミテッド | 哺乳動物血液を調整するための装置およびプロセス |
JP2003520244A (ja) * | 2000-01-18 | 2003-07-02 | バソジェン アイルランド リミテッド | 前処理した自己血液によるうっ血性心不全の処置 |
JP2009167223A (ja) * | 2001-11-13 | 2009-07-30 | Univ Duke | 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用 |
JP2019065039A (ja) * | 2013-02-28 | 2019-04-25 | ニュー・ヘルス・サイエンシーズ・インコーポレイテッドNew Health Sciences, Inc. | 血液処理のためのガス枯渇化およびガス添加デバイス |
JP2017521088A (ja) * | 2014-05-09 | 2017-08-03 | サンクステム エス・アール・エル | 全血から成体幹細胞を増殖させる方法 |
Also Published As
Publication number | Publication date |
---|---|
AU3506393A (en) | 1993-09-03 |
DK1243278T3 (da) | 2007-05-07 |
DK0680346T3 (da) | 2002-10-28 |
EP0680346A1 (en) | 1995-11-08 |
ATE219953T1 (de) | 2002-07-15 |
ES2179828T3 (es) | 2003-02-01 |
EP1243278A3 (en) | 2003-02-26 |
ES2280454T3 (es) | 2007-09-16 |
WO1993015779A1 (en) | 1993-08-19 |
CA2129630A1 (en) | 1993-08-08 |
US5834030A (en) | 1998-11-10 |
DE69332087D1 (de) | 2002-08-08 |
DE69334101D1 (de) | 2007-02-15 |
DE69332087T2 (de) | 2002-10-24 |
EP1243278A2 (en) | 2002-09-25 |
AU681999B2 (en) | 1997-09-18 |
HK1053068A1 (en) | 2003-10-10 |
EP1243278B1 (en) | 2007-01-03 |
EP0680346B1 (en) | 2002-07-03 |
ATE350046T1 (de) | 2007-01-15 |
NZ249176A (en) | 1996-11-26 |
PT680346E (pt) | 2002-10-31 |
DE69334101T2 (de) | 2007-10-04 |
CA2129630C (en) | 2003-09-23 |
HK1053068B (zh) | 2007-03-30 |
PT1243278E (pt) | 2007-04-30 |
JP3989949B2 (ja) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07503722A (ja) | 血中の酸化窒素濃度を増加させる方法 | |
Bocci | Ozone as Janus: this controversial gas can be either toxic or medically useful | |
US5591457A (en) | Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human | |
Cavarocchi et al. | Superoxide generation during cardiopulmonary bypass: is there a role for vitamin E? | |
Saniabadi et al. | Vessel wall injury and arterial thrombosis induced by a photochemical reaction | |
US7223391B2 (en) | Method for treating mammals with modified mammalian blood | |
Wu et al. | Ultraviolet blood irradiation: Is it time to remember “the cure that time forgot”? | |
Bocci et al. | Has oxygen-ozonetherapy a future in medicine? | |
Bocci et al. | Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes | |
Jani et al. | Ozone therapy: the alternative medicine of future | |
AU721530B2 (en) | Endothelial lining effects and treatment of vasospastic disorders | |
WO1993015778A1 (en) | Method of inhibiting the aggregation of blood platelets | |
EP1171140B1 (en) | Treatment of hypersensitivity reaction disorders | |
RU2153334C2 (ru) | Способ лечения онкологического заболевания | |
Rakovsky et al. | Application of ozone in medicine | |
Kontorshchikova et al. | Ozone Research Repository | |
AU760465B2 (en) | Endothelial lining effects and treatment of vasospastic disorders | |
Martusevich et al. | A comparative evaluation of the effects on the crystallogenic properties of the rat blood serum for prolonged inhalations of nitric oxide or reactive oxygen species | |
Beccerica et al. | Influence of Auranofin on Lymphocyte Membrane Fluidity in Rheumatoid Arthritis A Fluorescence Polarization Study | |
RU2278677C2 (ru) | Средство для стимулирования эритропоэза и устранения дефицита железа | |
KR20210019395A (ko) | 혈관건강 및 혈액흐름 촉진 효과와 암세포 살해를 통한 항암작용 그리고 갱년기 중, 장년층의 성기능 개선효능을 가지는 것을 특징으로 하는 머위와 삼백초와 홍경천 추출 복합물의 제조방법. | |
Putra et al. | THE EFFECT OF 3000 mg INTRAVENOUS VITAMIN C ON SERUM NITRIC OXIDE LEVEL OF SEVERE BURNT INJURY PATIENTS | |
Charafi et al. | Traditional Medicinal System | |
Deshmukh | ALTERATIONS IN IMMUNOLOGICAL PROTEIN VALUE AFTER LEECH THERAPY | |
Abd et al. | Middle East Journal of Applied Sciences Volume: 13| Issue: 01| Jan.–Mar.| 2023 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20051129 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20051129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060725 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060921 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070710 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070719 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100727 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |